Brightseed, which develops an AI-based system called Forager to identify and categorize plant compounds for human health, raises a $68M Series B led by Temasek
Devin Coldewey / TechCrunch : Tweets: @eleavenworth , @mehabecapital , and @420intel Tweets: Elaine Leavenworth / @eleavenworth : @Brightseed is moving forward with #AI that unlocks powerful plant compounds for health benefits With A $120 Million War Chest. @Forbes #plant-basedhealth #bioactives #AI150 https://www.forbes.com/... @mehabecapital : A company called Brightseed is bringing the first ever compounds discovered by AI to commercial launch. They say AI has detected plant compounds that substantially reduce fat around the liver. - #Future https://mehabe.com/... @420intel : Cannabis is not the only plant the company is researching. Brightseed is on a mission to catalog the bioactive compounds in the approximate 60,000 edible plant species. http://420intel.com/... #cannabisindustry https://twitter.com/...
Context & Ripple Effects
Brightseed's raise slots into a decade-long arc of AI pointed at biology: London's BenevolentAI set the template with $115M at a $2.1B valuation back in 2018, and more recently Enveda extended the playbook with $55M Series B extension funding for AI-plus-remedies drug discovery. Brightseed's twist is the target market — rather than prescription drugs, its Forager system hunts bioactives, plant compounds with human-health benefits, and per the surrounding coverage its first AI-discovered compounds are headed for commercial launch.
The lead investor matters as much as the amount. Temasek's broader record includes write-downs on collapsed startups such as FTX and a reported pullback from startup investing, so its choice to lead this round reads as a signal of where the sovereign fund still sees durable value — applied biology rather than consumer internet.
First-order effects
- Brightseed leaves the round with a reported ~$120M war chest to push Forager's first AI-discovered compounds — including ones it says substantially reduce fat around the liver — through commercialization.
- Temasek takes a lead position in bioactive discovery, deepening an agritech-and-biology exposure that already includes stakes in ventures like eFishery.
Second-order effects
- Funded peers BenevolentAI and Enveda gain validation that the AI-discovery model pays outside traditional pharma pipelines, widening the buyer base to food, supplement, and wellness brands.
- Ingredient suppliers and consumer-health formulators face a new class of AI-validated bioactives competing for shelf space and R&D budgets.
Third-order effects
- If AI-discovered compounds clear regulatory and commercial hurdles, compound discovery in nutrition shifts from lab-first screening to algorithm-first targeting, shrinking the role of conventional screening R&D.
- The string of large rounds across the space — BenevolentAI, BrightInsight's $101M Series C, Enveda, and now Brightseed — points to AI-biology hardening into its own funding vertical with dedicated institutional capital.
The trend: AI is expanding from drug discovery into everyday nutrition, as investors bet algorithms can surface commercially viable plant compounds faster than laboratory screening can.